Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tryton Medical appoints new CEO
Mr Davis joins Tryton Medical after a successful 20-year career with Guidant and Eli Lilly & Company. Most recently he was president of Guidant, Japan with profit and
Mr Davis joins Tryton Medical after a successful 20-year career with Guidant and Eli Lilly & Company. Most recently he was president of Guidant, Japan with profit and
This Phase II study investigated the efficacy of BIBF 1120 in 73 patients with an ECOG score of 0-2 with locally advanced or metastatic non-small cell lung cancer
The Early study is an open-label, randomized, viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) positive patients, comparing the antiviral activity of Baraclude and adefovir.
Efficacy has been shown in idiopathic pulmonary arterial hypertension (PAH) and in PAH associated with connective tissue disease. Volibris (ambrisentan) offers the convenience of a once-daily oral tablet
The pivotal, Phase III study is being led by the National Cancer Institute, which previously approved the study’s expansion to a multi-center trial. University of Maryland Medical Center
Pfizer is funding the three-year and $14 million Insulin Resistance Pathway (IRP) Project to look at insulin signaling in adipose (fat) cells to increase understanding of diabetes and
In a 28-week treatment regimen in which patients received four weeks of Pegintron and Rebetol prior to the addition of boceprevir (800mg TID), the rate of sustained virological
Under terms of the agreement, the company will sell 4.58 million shares of its common stock at $1.73 per share. As part of the transaction, the investors also
The positive opinion recommends grant of a conditional marketing authorization. The revised positive opinion has been issued following review by the CHMP of new data received in February
The orphan designation is for the preventative treatment of erythropoietic porphyrias (metabolic blood disorders). The designated diseases, erythropoietic porphyrias (EPP), are classified as severe and rare genetic diseases